RSV MAT-004: A Phase II observer-blind study to assess safety, reactogenicity, and immunogenicity of GSK Biologicals’ investigational RSV Maternal unadjuvanted vaccine (GSK3888550A), in healthy pregnant women and infants born to vaccinated mothers

    Project Details

    StatusFinished
    Effective start/end date11/11/1910/11/20

    Funding

    • GlaxoSmithKline: AUD38,368.00
    • GlaxoSmithKline: AUD236,977.00